Reaction: Niraparib to 1 product
- Reaction
- Reaction type
- Amide Hydrolysis
- Direction
- Major circulating metabolite?
- Yes
- Spontaneous?
- No
- Activity
- inactive
- References
- van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH: Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2. Epub 2017 Mar 16. [Article]
- FDA Approved Drug Products: ZEJULA (niraparib) capsules, for oral use (September 2022) [Link]
- EMA Approved Drug Products: Zejula (niraparib) Oral Capsules [Link]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Human Carboxylesterases Not Available Not Available implied
